623 reports of this reaction
1.3% of all HALOPERIDOL reports
#19 most reported adverse reaction
ELECTROCARDIOGRAM QT PROLONGED is the #19 most commonly reported adverse reaction for HALOPERIDOL, manufactured by Advagen Pharma Ltd. There are 623 FDA adverse event reports linking HALOPERIDOL to ELECTROCARDIOGRAM QT PROLONGED. This represents approximately 1.3% of all 49,192 adverse event reports for this drug.
Patients taking HALOPERIDOL who experience electrocardiogram qt prolonged should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ELECTROCARDIOGRAM QT PROLONGED is a less commonly reported adverse event for HALOPERIDOL, but still significant enough to appear in the safety profile.
In addition to electrocardiogram qt prolonged, the following adverse reactions have been reported for HALOPERIDOL:
The following drugs have also been linked to electrocardiogram qt prolonged in FDA adverse event reports:
ELECTROCARDIOGRAM QT PROLONGED has been reported as an adverse event in 623 FDA reports for HALOPERIDOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
ELECTROCARDIOGRAM QT PROLONGED accounts for approximately 1.3% of all adverse event reports for HALOPERIDOL, making it a notable side effect.
If you experience electrocardiogram qt prolonged while taking HALOPERIDOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.